{
    "clinical_study": {
        "@rank": "58572", 
        "arm_group": [
            {
                "arm_group_label": "Anatabloc Cream", 
                "arm_group_type": "Active Comparator", 
                "description": "Twice daily use of active facial cream"
            }, 
            {
                "arm_group_label": "Placebo Cream", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Twice daily use of placebo facial cream"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a multi-site, four-visit, eight-week, double-blind, randomized, vehicle-controlled,\n      parallel-group study followed by an eight-week open-label extension to evaluate the safety,\n      tolerability, and potential effects of Anatabloc Facial Cream.  The secondary aim is to\n      evaluate if Anatabloc Facial Cream improves the appearance of the skin in subjects with mild\n      to moderate rosacea."
        }, 
        "brief_title": "A Study to Evaluate the Safety, Tolerability, and Effects of Anatabloc\u00ae Cr\u00e8me in Rosacea", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Rosacea", 
        "condition_browse": {
            "mesh_term": "Rosacea"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  age between 25-70 years\n\n          -  diagnosed with mild to moderate rosacea\n\n        Exclusion Criteria:\n\n          -  allergy or sensitivity to the study products or their components\n\n          -  severe rosacea\n\n          -  current use of glucocorticoids, anti-acne products, antibiotics,  topical retinoids,\n             or vasoactive drugs\n\n          -  recent oral isotretinoin use\n\n          -  current use of anatabine-containing supplements (ie. Anatabloc, Anatabloc Unflavored,\n             CigRx)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Years", 
            "minimum_age": "25 Years"
        }, 
        "enrollment": {
            "#text": "117", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 30, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01740934", 
            "org_study_id": "RCP-012"
        }, 
        "intervention": [
            {
                "arm_group_label": "Anatabloc Cream", 
                "intervention_name": "Anatabloc Cream", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Placebo Cream", 
                "intervention_name": "Placebo Cream", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "rosacea", 
            "anatabine", 
            "Anatabloc", 
            "dermatology"
        ], 
        "lastchanged_date": "April 29, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bradenton", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34209"
                    }, 
                    "name": "Susan H. Weinkle, MD"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Orleans", 
                        "country": "United States", 
                        "state": "Louisiana", 
                        "zip": "70124"
                    }, 
                    "name": "Lupo Center for Aesthetic & General Dermatology"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10022"
                    }, 
                    "name": "Diane Berson, MD"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Eight-Week, Multi-Site, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Trial to Evaluate the Safety, Tolerability, and Effects of Anatabloc\u00ae Cr\u00e8me in Subjects With Rosacea Followed by an Open-Label Extension", 
        "overall_official": {
            "affiliation": "Star Scientific", 
            "last_name": "M Varga, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Collected information of the safety, tolerability and adverse events, and subjective experience related to the use of Anatabloc Cream by subjects", 
            "measure": "Adverse Effects", 
            "safety_issue": "No", 
            "time_frame": "8 to 16 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01740934"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Change measured by comparison of questionnaire and rating scores over time", 
            "measure": "Change in the appearance of the facial skin", 
            "safety_issue": "No", 
            "time_frame": "8 to 16 weeks"
        }, 
        "source": "Rock Creek Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Rock Creek Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}